Dysrhythmia

Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates

Retrieved on: 
Tuesday, March 19, 2024
Diary, Patient, IND, Adolescence, Pediatrics, Therapy, FAAP, Rett syndrome, Research, Central nervous system, Risk, Webcast, CNS, Ageing, CHU, Safety, AAV, Mutation, Development, MECP2, Disease, Associate, Sleep, Șaeș, Dysrhythmia, FRCP, MTD, Movement, IDMC, VG, Hyperventilation, Principal, Administration, Index, Seizure, CTA, Female, MHRA, Phenotype, ID, Frasier, Pharmaceutical industry

Notably, she has vastly increased interest in social communication and activities at week 35 compared to earlier post-treatment assessments.

Key Points: 
  • Notably, she has vastly increased interest in social communication and activities at week 35 compared to earlier post-treatment assessments.
  • Dr. Schultz is a board-certified, licensed pediatric neurologist experienced in treating patients with Rett syndrome and leading gene therapy clinical trials.
  • She brings more than 17 years of clinical experience and will lead the Company’s clinical development, clinical operations, medical affairs and safety activities.
  • ET to review its financial and operating results and to provide corporate and clinical updates.

Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Retrieved on: 
Tuesday, November 14, 2023
CNS, Webcast, Principal, ID, Associate, Gait, Safety, Pediatrics, Gene, Silicon Valley Bank, Socialization, Phenotype, Disease, Risk, Clinical trial, CHU, Administration, Patient, Cell, Dysrhythmia, FAAP, Research, ESGCT, Movement, Posture, Seizure, Hyperventilation, Development, IDMC, FRCP, Rett syndrome, Congress, Central nervous system, Mutation, Walking, Șaeș, AAV, MECP2, Pharmaceutical industry, Nursing, Vaccine, Cryptocurrency, Rett, DALLAS, Neuroscience

Following treatment, both patients experienced improvement in key clinical domains impacting activities of daily living, including breathing dysrhythmia, autonomic function, socialization, and gross and fine motor skills.

Key Points: 
  • Following treatment, both patients experienced improvement in key clinical domains impacting activities of daily living, including breathing dysrhythmia, autonomic function, socialization, and gross and fine motor skills.
  • Additional information on available clinical data is available in the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2023, to be filed with the SEC.
  • Cash and cash equivalents: As of September 30, 2023, the Company had cash and cash equivalents of $164.3 million.
  • Taysha management will hold a conference call and webcast today at 4:30 pm ET to review its financial and operating results and to provide corporate and clinical updates.

ASA Recognizes Best Job Training Programs in the U.S. Staffing Industry

Retrieved on: 
Thursday, September 21, 2023
Workforce, ASA, Maintenance, Charlotte Convention Center, TJC, Employment, Joint Commission, Staffing, American Staffing Association, Dysrhythmia, Certification, RELN, Joint, Patient, Patient safety, Nomad Health, Allied health professions, Real estate, Nursing

Created in 2018, the Elevate Awards celebrate the staffing industry's most innovative workforce development programs for temporary and contract employees.

Key Points: 
  • Created in 2018, the Elevate Awards celebrate the staffing industry's most innovative workforce development programs for temporary and contract employees.
  • "The ASA Elevate Award highlights the staffing industry's commitment to helping people future-proof their careers through training, upskilling, and reskilling," said Richard Wahlquist, chief executive officer at ASA.
  • Award winners will be honored during a ceremony at Staffing World®, the ASA annual convention and expo, Oct. 3-5 at the Charlotte Convention Center in Charlotte, NC.
  • Since the introduction of the program, JWilliams Staffing has awarded more than 1,500 career certifications through RELN.

Vizient Examines Care Models for Arrhythmia, How to Improve Screening Rates for Colorectal Cancer in Latest Medical Device Tech Watch

Retrieved on: 
Thursday, April 13, 2023
Cardiology, Medical Supplies, Biotechnology, Practice Management, Technology, Health, Oncology, Medical Devices, Artificial Intelligence, Hospitals, Surgery, Heart Rhythm Society, Vizient, Inc., Prevalence, CRC, Arrhythmia, Ventricular fibrillation, Cancer, Intelligence, Large intestine, Dysrhythmia, Sterilization, Colorectal cancer, Patient, Korea Disease Control and Prevention Agency, EP, Artificial intelligence, Death, Organization, Medical device

Vizient, Inc. released its latest Medical Device Tech Watch, examining care models for cardiac arrhythmia, methods for improving colorectal cancer screening rates and how optimizing surgical tray standardization can reduce costs and improve operational efficiencies.

Key Points: 
  • Vizient, Inc. released its latest Medical Device Tech Watch, examining care models for cardiac arrhythmia, methods for improving colorectal cancer screening rates and how optimizing surgical tray standardization can reduce costs and improve operational efficiencies.
  • “This edition of Tech Watch explores a variety of topics, including emerging artificial intelligence technologies and efficiencies in the operating room,” said Doug Beinborn, associate principal, Vizient.
  • Vizient conducted a tray standardization initiative with a member-provider, identifying ways to reduce costs and improve efficiency without impacting clinicians or patient care.
  • Tech Watch delivers data-driven insights on trends and dynamics affecting healthcare, providing insights that drive innovation in care delivery.

Mark Y. Lee, M.D., Named Medical Director of Electrophysiology at MemorialCare Heart & Vascular Institute at Long Beach Medical Center

Retrieved on: 
Thursday, January 19, 2023
Long Beach Medical Center, University, Cardiac electrophysiology, Education, FACC, Dartmouth–Hitchcock Medical Center, Cardiovascular disease, Internal medicine, Dysrhythmia, Ventricular tachycardia, Supraventricular tachycardia, Atrial fibrillation, Flecainide, Patient, Clinical trial, EP, Electrophysiology, Research, Hospital, Medical device

LONG BEACH, Calif., Jan. 19, 2023 /PRNewswire/ -- Mark Y. Lee, M.D ., FACC, has been named medical director of electrophysiology at MemorialCare Heart & Vascular Institute at Long Beach Medical Center .

Key Points: 
  • LONG BEACH, Calif., Jan. 19, 2023 /PRNewswire/ -- Mark Y. Lee, M.D ., FACC, has been named medical director of electrophysiology at MemorialCare Heart & Vascular Institute at Long Beach Medical Center .
  • As the new medical director of electrophysiology, Dr. Lee will work to further Long Beach Medical Center's efforts for electrophysiology clinical research and education.
  • "Dr. Lee has done amazing work to date at MemorialCare Heart & Vascular Institute at Long Beach Medical Center, and we are excited to have him take on this new role as medical director of electrophysiology," says Joe Kim, M.D., chief medical officer, MemorialCare Long Beach Medical Center.
  • "I was born at Long Beach Medical Center, so serving my local community these past seven years as an electrophysiologist has been a blessing," says Dr. Lee.

CorMedix Inc. Announces Abstract Presentation at Upcoming American Society of Nephrology Conference

Retrieved on: 
Thursday, October 20, 2022
API, ASN, CVC, QIDP, Mortality, PVD, LTC, Moyamoya disease, HD, Cancer, American Society of Nephrology, CRL, Urinary tract infection, Pneumonia, MI, CMS, LTCS, Private Securities Litigation Reform Act, Company, Marketing, Heart failure, IP, Incidence, Heparin, GLOBE, CMO, FDA, Myocardial infarction, Female, Risk, Stroke, Endpoint security, Society, Research, Goal, Trial of the century, HF, NTAP, Gangrene, SEC, Dialysis, New Drug Application, NDA, Patient, Nasdaq, New chemical entity, Medicare, Disease, Dysrhythmia, Fast Track, Kidney failure, African Americans, OP, Pharmaceutical industry, Coronavirus

The abstract being presented highlights a retrospective analysis that was conducted integrating multiple clinical and claims databases that track kidney failure patients.

Key Points: 
  • The abstract being presented highlights a retrospective analysis that was conducted integrating multiple clinical and claims databases that track kidney failure patients.
  • CorMedix has demonstrated in a Phase 3 clinical study that DefenCath can reduce the incidence of CRBSIs in CVC patients undergoing hemodialysis by approximately 71%.
  • The abstract is included below and available through the American Society of Nephrology conference website.
  • CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

OMNIVISION Launches ‘Ready-to-Go’ Reference Designs for High Definition Video Single-Use Laryngoscopes

Retrieved on: 
Monday, April 11, 2022
Semiconductor, Medical Devices, Health, Technology, Hospitals, Photography, Larynx, Ayar, CAGR, DVP, VGA, 720p, Intubation, Anaheim Convention Center, Death, CMOS, Multimedia, Dysrhythmia, Original equipment manufacturer, 1, RAW, Field of view, Laryngoscopy, MD, Health, Time, COVID-19, RISC, Mark (given name), Patient, Algorithm, Medical imaging, Camera

View the full release here: https://www.businesswire.com/news/home/20220411005331/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220411005331/en/
    OMNIVISIONs ready-to-go reference designs help medical device OEMs speed time-to-market in the development of laryngoscopes.
  • The video laryngoscope, a device used in the visualization of the airway, is quickly displacing traditional direct laryngoscopy, said Ehsan Ayar, product marketing manager at OMNIVISION.
  • OV788a single-chip, high definition video/audio processor that features ultra-low power consumption, fast boot-up, small footprint and requires no external memory.
  • OMNIVISION, OmniBSI, OmniBSI +, CameraCubeChip and the OMNIVISION logo are trademarks or registered trademarks of OMNIVISION.

Cardiol Therapeutics Announces Year-End 2021 Update on Operations

Retrieved on: 
Thursday, March 24, 2022
People, Risk, Therapy, Biomarker, Management, Vaccine, Research, Biotechnology, Amgen, Goal, Cardiology, Dysrhythmia, Nasdaq, Pericarditis, Regulation of tobacco by the U.S. Food and Drug Administration, COVID-19, Fibrosis, Houston, Heart failure, History, Disease, Heart, Cornell University, Diagnosis, Analysis, SEDAR, Myocarditis, Health, Quality of life, Industry, Weill Cornell Medicine, Houston Methodist Hospital, Pulmonary embolism, Phase, Hospital, Cancer, NASDAQ, Financial statement, Death, Infarction, Board, CMO, CVD, Cardiovascular disease, Conversation, Board of directors, Inflammation, Awareness, FDA, Patient, Company, CRDL, Cannabidiol, IND, Food, TSX, Safety, Stroke, Degenerative disease, News, Infection, Pharmaceutical industry, Medicine

David Elsley, President and Chief Executive Officer of Cardiol Therapeutics, commented: "In 2021 Cardiol Therapeutics accomplished several important goals.

Key Points: 
  • David Elsley, President and Chief Executive Officer of Cardiol Therapeutics, commented: "In 2021 Cardiol Therapeutics accomplished several important goals.
  • Dr. Hamer leads the research and development of Cardiol's clinical-stage products and guides the development of additional novel therapeutics in the Company's pipeline.
  • In April, Cardiol released topline results from a Phase I single and multiple ascending dose clinical trial of CardiolRx.
  • Raised $98 million in gross proceeds from financings completed during 2021, ending the year with cash and cash equivalents of $83.9M.

Cardiol Therapeutics Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments Designed to Expedite Patient Enrollment in the LANCER Trial

Retrieved on: 
Tuesday, March 1, 2022
Risk, Diagnosis, Pericarditis, TSX, Patient, Heart, Standard of care, Research, Biomarker, Population, Pneumonia, Heart failure, Myocarditis, Safety, CRDL, News, Cardiovascular disease, FDA, CVD, Committee, Therapy, Infarction, Smoking, Company, COVID-19, Mortal Kombat, Disease, Inflammation, Obesity, Clinical trial, Degenerative disease, History, Stroke, CGMP, Mortality, Diabetes, Investigational New Drug, Pulmonary embolism, Hypertension, Dysrhythmia, Dyslipidemia, NASDAQ, Pharmaceutical industry

LANCER Trial expanded to include up to 20 Additional Clinical Research Centers

Key Points: 
  • The Company expects the LANCER trial to achieve over 50% patient recruitment by the end of the first half of 2022 and to complete full patient enrollment during the second half of 2022.
  • Interest in the LANCER trial remains strong, and Cardiol continues to activate new clinical research sites to accelerate patient recruitment," stated Dr. Andrew Hamer, Chief Medical Officer of Cardiol Therapeutics.
  • Despite challenges resulting from ongoing changes to the standard of care, we are confident that the recently cleared protocol amendments will help ensure our LANCER patient enrollment targets are achieved."
  • The LANCER trial was designed and is being overseen by an independent Steering Committee, consisting of international thought leaders in inflammatory heart disease.